Get started
Work

1540P Ripretinib as ≥4th-line treatment in patients with advanced gastrointestinal stromal tumor: Long-term update from the phase III INVICTUS study

Year: 2021
Type: article
DOI: 10.1016/j.annonc.2021.08.870
Authors: M. von Mehren, M.C. Heinrich, S. George, J.R. Zalcberg, S. Bauer, H. Gelderblom, P. Schöffski, C. Serrano, R.L. Jones, S. Attia, G. D'Amato, P. Chi, P. Reichardt, J.N. Meade, V.L. Reichert, K. Shi, R. Ruiz-Soto, J-Y. Blay
Institutions: Fox Chase Cancer Center, Oregon Health & Science University, OHSU Knight Cancer Institute, Dana-Farber Cancer Institute, Monash University, Essen University Hospital, Stiftung Universitätsmedizin Essen, Leiden University Medical Center, Universitair Ziekenhuis Leuven, KU Leuven, Vall d'Hebron Institute of Oncology, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, Mayo Clinic, Mayo Clinic Comprehensive Cancer Center (Florida), University of Miami, Sylvester Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Helios Hospital Berlin-Buch, Deciphera Pharmaceuticals (United States), Centre Léon Bérard
Language: English
Field: Medicine
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, American Society of Clinical Oncology, Alnylam Pharmaceuticals, Karyopharm Therapeutics, Exelixis, PTC Therapeutics, Incyte, Springworks Therapeutics, Eisai, Astellas Pharma, Servier, PharmaMar, Bavarian Nordic, Daiichi Sankyo Europe
OpenAlex ID: W3201660419
FWCI: 2.442
Cites:
Cited by: 18
Related to: 10